UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______. Commission File Number 001-41822 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organizati ...

Carmel, Ind., March 12, 2026 / PRNewswire – Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today its financial results for the fourth quarter and full year ended December 31, 2025. Q4 and Full Year 2025 Financial Highlights 2026 Financial Outlook ● The Company expects to achieve profitability by year-end 2026, driven by continued strong dem ...

Core Insights - Syra Health reported a strong financial performance for FY2025, with a 157% growth in population health revenue and a 76% reduction in net loss, targeting profitability by the end of 2026 [1][2] Financial Performance - Population health revenue increased to $5.3 million in FY2025 from $2.1 million in FY2024, marking a 157% year-over-year growth [1] - Total revenue for FY2025 was $7.2 million, a 9% decrease from $8.0 million in FY2024, primarily due to reduced federal government funding [1][2] - Net loss improved to ($896K) in FY2025 from ($3.8M) in FY2024, reflecting a 76% reduction [1][2] - Earnings per share (EPS) improved to ($0.08) in FY2025 from ($0.50) in FY2024 [1] - Gross margin increased to 34.4% in FY2025 from 20.7% in FY2024, a 14 percentage point rise attributed to better operational efficiency [1] Operational Highlights - Operating expenses decreased by 37% to $3.4 million in FY2025 compared to $5.4 million in FY2024 [1] - The company launched a wellness pilot program in collaboration with a public health department in North Carolina [1] - Syra Health submitted Syrenity for FDA approval under the TEMPO pilot program, aiming to participate in CMS's ACCESS Model starting July 2026 [1] Future Outlook - The company anticipates achieving profitability by year-end 2026, driven by strong demand for its population health solutions and disciplined cost management [1] - Management expressed confidence in the company's path to profitability, highlighting the combination of revenue growth and cost restructuring [1]

Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results Accessibility Statement Skip NavigationCARMEL, Ind., March 5, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that it will report financial results for its fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 12, 2026 ...

Core Insights - Syra Health Corp. has appointed Gregory R. Alexander as the new Chief Executive Officer, effective January 5, 2026, to drive growth and market expansion [1][3] Company Overview - Syra Health is a healthcare solutions company focused on improving health outcomes through prevention-focused, accessible, and affordable solutions [1][7] - The company specializes in healthcare prevention, expanding access, and delivering affordable solutions, with capabilities in healthcare analytics and digital health solutions [7] Leadership Background - Gregory R. Alexander has over two decades of P&L experience and a proven track record in driving growth, operational excellence, and strategic change in managed care, population health, and healthcare technology [2][3] - His previous roles include Senior Vice President of Commercial at Ellipsis Health and Chief Growth Officer at CitizensRx, where he implemented growth strategies that tripled sales [4] Strategic Goals - Alexander's leadership is expected to accelerate Syra Health's growth strategy, leveraging his expertise in Medicare, Medicaid, and population health services [3][5] - The company aims to expand its market presence and deliver greater value to customers, shareholders, and communities [5] Community Engagement - Alexander is a long-time resident of Carmel, Indiana, and has led significant healthcare initiatives in the state, including supporting Indiana University Health System's $600 million health plan [5]

Revenue Performance - Net revenues for the three months ended September 30, 2025, were $1,687,971, a decrease of $565,365 or 25% compared to $2,253,336 in the same period of 2024 [108]. - For the nine months ended September 30, 2025, net revenues were $5,491,944, a decrease of $483,413 or 8% compared to $5,975,357 in the same period of 2024 [121]. - Population health revenue increased to $1,280,011 in Q3 2025 from $652,298 in Q3 2024, an increase of $627,713 or 96% [110]. Expenses and Cost Management - Operating expenses for the three months ended September 30, 2025, were $786,712, a decrease of $310,496 or 28% from $1,097,208 in Q3 2024 [108]. - The company incurred $3,595,352 in cost of services for the nine months ended September 30, 2025, a decrease of $1,061,921 or 23% from $4,657,273 in the same period of 2024 [123]. - Salaries and benefits decreased by $1,008,154 or 46% to $1,169,951 for the nine months ended September 30, 2025, compared to $2,178,105 in the same period of 2024 [121]. - Research and development expenses dropped to $67,701 for the nine months ended September 30, 2025, a decrease of $522,562 or 89% from $590,263 in the same period of 2024 [122]. - Selling, General and Administrative (SG&A) expenses decreased by $438,893, or 35%, to $828,741 for the nine months ended September 30, 2025, compared to $1,267,634 in the same period of 2024, driven by efforts to reduce overhead [128]. - Professional fees increased by $90,852, or 19%, to $580,691 for the nine months ended September 30, 2025, compared to $489,839 in the same period of 2024, primarily due to increased legal and accounting costs [126]. Profitability and Loss - The company reported a net loss of $225,902 for the three months ended September 30, 2025, compared to a net loss of $417,535 in the same period of 2024, a decrease of $191,633 [119]. - Net loss for the nine months ended September 30, 2025, was $761,763, a decrease of $2,493,078 compared to a net loss of $3,254,841 in the same period of 2024 [131]. Cash Flow and Liquidity - Cash used in operating activities improved to $158,554 for the nine months ended September 30, 2025, compared to $2,717,313 in the same period of 2024, reflecting better expense management [136]. - Cash used in investing activities was $0 for the nine months ended September 30, 2025, compared to $11,111 in the same period of 2024, indicating a halt in property and equipment purchases [137]. - The company anticipates that existing liquidity sources will not be sufficient to fund operations for at least the next twelve months, indicating a potential need for additional financing [132]. Assets and Liabilities - Current assets decreased to $3,210,591 as of September 30, 2025, from $3,352,795 as of December 31, 2024, while current liabilities increased to $1,053,829 from $613,549 in the same period [134]. Future Outlook - The company has begun to see delays in new contract awards and cancellations of previous requests for proposals due to changes in federal spending programs, which may negatively affect future revenues [110]. - For the nine months ended September 30, 2025, approximately 59% of revenues were derived from the Indiana Family and Social Services Administration (FSSA), with significant contributions from various divisions [151].

Financial Performance - Q3 2025 revenue was $1.7 million, a decrease from $2.3 million in Q3 2024, primarily due to federal spending cuts impacting state and county government budgets [7] - Net loss decreased by 46% year-over-year to ($225,902) from ($417,535) in Q3 2024, reflecting improved operational efficiency [4] - Adjusted EBITDA improved to ($218,601) in Q3 2025 compared to ($389,728) in Q3 2024, indicating better operational performance [10] Revenue Growth - Population Health segment revenue grew 96% year-over-year to $1,280,011, driven by successful upselling to state health departments and private sector customers [4] Cost Management - Total operating expenses declined by 28% to $786,712 in Q3 2025 from $1,097,208 in the prior year, driven by disciplined cost management [9] - Salaries and benefits expenses decreased by 43% to $336,390 due to workforce optimization efforts [11] - Professional services expenses increased by 25% to $191,726 in Q3 2025, as external consultants were engaged to refine corporate strategy [11] - Research and Development expenses decreased by 98% to $816, reflecting a reduction in consulting expenses related to technology-based solutions [11] Cash Position - Cash and cash equivalents at the end of Q3 2025 were $1.98 million, with no long-term debt [13] Forward-Looking Statements - The company emphasizes that forward-looking statements are based on current expectations and are subject to substantial risks and uncertainties [25] - Investors are advised to review risk factors in the Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the SEC [25] - The company disclaims any obligation to update forward-looking statements unless required by federal securities laws [25]

Core Insights - Syra Health Corp. reported a decline in revenue for Q3 2025, primarily due to federal spending cuts impacting state and county government budgets, with revenue falling to $1.7 million from $2.3 million in Q3 2024 [5][7] - The Population Health business unit experienced significant growth of 96% year-over-year, indicating strong market demand for its solutions [3][8] - The company improved its gross margin by 300 basis points to 33% and reduced its net loss by 46% through cost management and operational efficiency [3][7] Financial Performance - Q3 2025 revenue was $1.7 million, down from $2.3 million in Q3 2024, largely due to federal budget cuts [5][14] - Population Health segment revenue reached $1,280,011, up from $652,298 in Q3 2024, driven by upselling to state health departments and private sector customers [8][14] - Gross margin improved to 33% in Q3 2025 from 30% in Q3 2024, attributed to a strategic focus on higher-margin business units [8][14] - Net loss decreased to ($225,902) in Q3 2025 from ($417,535) in Q3 2024, reflecting improved operational efficiency [7][14] Cost Management - Total operating expenses for Q3 2025 were $786,712, a 28% decline from $1,097,208 in the previous year, due to disciplined cost management [9][14] - Salaries and benefits decreased by 43% to $336,390, resulting from workforce optimization efforts [9][14] - Selling, general, and administrative expenses fell by 12% to $252,384 as part of overhead reduction initiatives [11][14] Strategic Focus - The company is refining its strategy to concentrate on its successful Population Health solutions, which is contributing to growth in its sales pipeline [4][5] - Syra Health's focus on targeted upselling and expansion into the private sector is expected to enhance its market position as federal budget clarity improves [4][5] Cash Position - As of September 30, 2025, Syra Health had cash and cash equivalents of $2.0 million and no long-term debt [11][12] - The company continues to manage its cash flow effectively, with a net cash used in operating activities of ($158,554) for the quarter [15]

Core Insights - Syra Health Corp. will report its financial results for the three months ended September 30, 2025, on November 12, 2025, before market opening [1]. Company Overview - Syra Health is a healthcare solutions company that serves both public and private healthcare organizations, focusing on innovative solutions that positively impact entire populations [2]. - The company specializes in healthcare prevention, expanding access, and delivering affordable solutions, with capabilities in healthcare analytics that provide proactive, actionable insights [2]. - Syra Health's digital health solutions are HIPAA-compliant and fully accessible, enabling measurable health outcomes in regulated healthcare environments [2]. - The company also emphasizes training and education to help healthcare organizations reduce costs and deliver consistent, high-quality care [2].

Company Performance Summary - aTyr Pharma, Inc. (ATYR) experienced a drastic stock price decrease of approximately 82.67%, falling to $1.04 from a year high of $7.29, with a trading volume surge to 125,060,529 [2][8] - Kindly MD, Inc. (NAKA) saw its stock price decline by 53.24% to $1.3 from a previous year high of $34.77, with a trading volume of 84,912,612 following the approval for options trading on the Nasdaq Options Market [3][8] - Syra Health Corp. Class A Common Stock (SYRA) reported a 40% decrease in stock price to $0.057 from a year high of $0.94, despite a 197% growth in its Population Health segment and an improvement in earnings per share [4][8] - Wearable Devices Ltd. (WLDSW) faced a stock price drop of 39.57% to $2.84, with a trading volume of 12,217, reflecting market concerns over its commercialization capabilities [5] - Longevity Health Holdings Inc. (XAGE) witnessed a 42.24% decline in stock price to $1.34, although a significant surge in stock price occurred after announcing a merger agreement with True Health Inc. [6] Market Dynamics - The significant price movements of these companies reflect a combination of company-specific developments, broader market trends, and investor sentiment [7] - Factors influencing stock prices include clinical trial outcomes, financial reports, regulatory news, and overall market dynamics [7]